Table 5: Adjusted1 hazard ratios for disease-specific and recurrence free survival.2

Risk FactorsOral cavityOropharynx
Disease-specific Survival1Recurrence-free survival1Disease-specific survival1Recurrence-free survival1
HR (95% CI)HR (95% CI)HR (95% CI)HR (95% CI)

Patients with HPV serology ( 𝑁 = 1 8 2 )
𝑁 = 1 1 6 𝑁 = 9 6 𝑁 = 5 2 𝑁 = 4 3
E6 and/or E7nnnn
 Negative103 (88.8)1.3 (0.4–4.2)86 (89.6)1.1 (0.3–3.6)16 (30.8)5.7 (1.7–20.0)13 (30.2)6.7 (1.7–26.1)
 Positive13 (11.2)1.010 (10.4)1.036 (69.2)1.030 (69.8)1.0
Age21.02 (1.0–1.1)1.02 (1.0–1.04)1.04 (0.96–1.1)1.03 (0.95–1.1)
Stage
 0/I/II1.01.01.01.0
 III/IV7.9 (2.8–22.5)1.5 (0.7–3.1)1.5 (0.2–11.4) 31.3 (0.03–58.8)

Patients with both HPV tumor and serology ( 𝑁 = 1 5 7 )
𝑁 = 1 0 0 𝑁 = 8 8 𝑁 = 4 4 𝑁 = 3 9

E6 and/or E7nnnn
 Negative89 (89.0)1.4 (0.4–4.5)80 (90.9)1.1 (0.3–3.5)14 (31.8)4.2 (1.2–15.1)12 (30.8)10.4 (2.4–52.4)
 Positive11 (11.0)1.08 (9.1)1.030 (68.2)1.027 (69.2)1.0
HPV tumor status
 Negative88 (88.0)0.8 (0.3–2.0)78 (88.6)0.5 (0.2–1.3)17 (38.6)3.0 (0.9–10.7)15 (38.5)7.3 (1.5–36.4)
 High Risk12 (12.0)1.010 (11.4)1.027 (61.4)1.024 (61.5)1.0

1Adjusted for stage and continuous age; 2in years; 3odds ratio Logit estimator adjusted for stage and categorical age.